BBLG Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
666.3K
-17.5%
808.1K
+0.4%
805.1K
+9.8%
733.1K
+2.5%
715.3K
R&D
242.6K
-21.4%
308.7K
+118.0%
141.6K
-44.9%
257.2K
+36.9%
187.8K
SG&A
423.8K
-15.1%
499.4K
-24.7%
663.5K
+39.4%
475.9K
-9.8%
527.5K
Operating Income
-666340
+17.5%
-808106
-0.4%
-805054
-9.8%
-733105
-2.5%
-715274
EBITDA
-666340
+17.5%
-808106
-0.4%
-805054
-9.8%
-733105
-2.5%
-715274
Net Income
-617651
+20.2%
-773702
-1.0%
-765988
-11.9%
-684643
-2.7%
-666737
EPS (Basic)
$-0.17
+60.5%
$-0.43
+0.0%
$-0.43
-13.2%
$-0.38
-2.7%
$-0.37
EPS (Diluted)
$-0.17
+60.5%
$-0.43
+0.0%
$-0.43
-13.2%
$-0.38
-2.7%
$-0.37
Shares (Diluted)
3.7M
+108.0%
1.8M
+0.1%
1.8M
-1.1%
1.8M
+1.2%
1.8M
Bone Biologics (BBLG) — Financials